We at GEPL have initiated coverage on Jubilant Organosys at the price of Rs 350 and a target of Rs 444 with a one year horizon. In the CRAMS segment which is due for a positive turnaround, Jubilant is one of the leading players. It is the one-stop destination providing contract research, custom synthesis, API manufacturing and dosage forms manufacturing as well. Its varied business segments are well poised for growth. The de-merger of the APP business segment is the trigger for value unlocking. The chain of acquisitions has augured well for the company. Also the company is enhancing capacities and investments across different business segments. Thus, Jubilant is strongly placed to capitalize on the emerging opportunities from the outsourcing market with growth visibility rendering valuations attractive for the company.
Published by geplcapital
Offering a range of financial services across investment spectrum, GEPL is a boutique financial services and investment advisory firm. It covers products such as equities, mutual funds, bonds, currencies, derivatives, commodities, wealth management, insurance, real estate, loan against securities and Demat services. GEPL provides single point access to all platforms through its mobile app & web platform, sound fundamental and technical reports, anytime / anywhere trade access & easy support over phone. Established in 1997, GEPL is headquartered in Mumbai, spread across 9 states and services through 150 access points including 25 own branches. With clientele ranging from individual investors to enterprises to institutions, GEPL intuitively understands different financial requirements and offers customized investment solutions. GEPL is firmly rooted by its 3 Mantras: Servicing, Integrity and Teamwork - all of which work to the benefit of clients. Apart from these 3 pillars, GEPL has combined it’s traditional advisory with modern technology and cutting edge research to meet and surpass it’s clients expectation. View all posts by geplcapital